F Janku
Overview
Explore the profile of F Janku including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gouda M, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, et al.
Ann Oncol
. 2023 Dec;
35(3):267-275.
PMID: 38145866
Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough...
2.
Janku F, Bauer S, Shoumariyeh K, Jones R, Spreafico A, Jennings J, et al.
ESMO Open
. 2022 Jun;
7(4):100520.
PMID: 35753087
Background: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor as ≥...
3.
Gouda M, Polivka J, Huang H, Treskova I, Pivovarcikova K, Fikrle T, et al.
ESMO Open
. 2021 Dec;
7(1):100357.
PMID: 34942440
Background: Implementation of adjuvant therapies in non-metastatic melanoma improved treatment outcomes in some patients; however, adjuvant therapy can be associated with significant cost and risk of toxicity. Therefore, there is...
4.
Dumbrava E, Call S, Huang H, Stuckett A, Madwani K, Adat A, et al.
ESMO Open
. 2021 Sep;
6(5):100230.
PMID: 34479035
Background: Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor...
5.
Cascone T, Sacks R, Subbiah I, Drobnitzky N, Piha-Paul S, Hong D, et al.
ESMO Open
. 2021 Mar;
6(2):100079.
PMID: 33721621
Background: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR),...
6.
Wu J, Liu D, Offin M, Lezcano C, Torrisi J, Brownstein S, et al.
Invest New Drugs
. 2021 Jan;
39(3):785-795.
PMID: 33389388
Background Ulixertinib is the first-in-class ERK1/2 kinase inhibitor with encouraging clinical activity in BRAF- and NRAS-mutant cancers. Dermatologic adverse events (dAEs) are common with ulixertinib, so management guidelines like those...
7.
Li B, Janku F, Jung B, Hou C, Madwani K, Alden R, et al.
Ann Oncol
. 2019 Mar;
30(4):597-603.
PMID: 30891595
Background: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to...
8.
Liu L, Toung J, Jassowicz A, Vijayaraghavan R, Kang H, Zhang R, et al.
Ann Oncol
. 2018 Apr;
29(6):1445-1453.
PMID: 29635542
Background: Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a potential to expand liquid biopsies to patients with tumors without detectable oncogenic alterations, which can be potentially useful in...
9.
Janku F, Johnson L, Karp D, Atkins J, Singleton P, Moss J
Ann Oncol
. 2017 Dec;
29(4):1076.
PMID: 29253076
No abstract available.
10.
Janku F, Huang H, Fujii T, Shelton D, Madwani K, Fu S, et al.
Ann Oncol
. 2016 Dec;
28(3):642-650.
PMID: 27993791
Background: Cell-free DNA (cfDNA) from plasma offers easily obtainable material for KRAS mutation analysis. Novel, multiplex, and accurate diagnostic systems using small amounts of DNA are needed to further the...